• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

滤泡性淋巴瘤的流行病学。

Epidemiology of Follicular Lymphoma.

机构信息

Department of Health Sciences Research, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA.

出版信息

Hematol Oncol Clin North Am. 2020 Aug;34(4):631-646. doi: 10.1016/j.hoc.2020.02.001. Epub 2020 May 5.

DOI:10.1016/j.hoc.2020.02.001
PMID:32586570
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7323888/
Abstract

Follicular lymphoma (FL) is a common indolent lymphoma subtype in Western countries. FL incidence increases with age, and shows considerable variation by race/ethnicity and geography. In the United States and France, FL incidence has been stable since 2000, whereas in other Western and Asian countries it has been increasing. Five-year relative survival rates have been increasing in Western and Asian countries. Progress on identifying FL-specific risk factors has accelerated with the implementation of the InterLymph nested classification and the availability of larger epidemiologic studies and pooled analyses. Identification of risk factors for FL requires further research.

摘要

滤泡性淋巴瘤(FL)是西方国家常见的惰性淋巴瘤亚型。FL 的发病率随年龄增长而增加,且在种族/民族和地理位置上存在显著差异。在美国和法国,自 2000 年以来 FL 的发病率一直保持稳定,而在其他西方国家和亚洲国家则呈上升趋势。西方国家和亚洲国家的五年相对生存率一直在提高。随着 InterLymph 巢式分类的实施,以及更大规模的流行病学研究和汇总分析的出现,鉴定 FL 特异性危险因素的进展加速。进一步研究仍需要确定 FL 的危险因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d32/7323888/16b7b74c36f7/nihms-1568549-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d32/7323888/7455a962e04e/nihms-1568549-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d32/7323888/30a9ef30bbb1/nihms-1568549-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d32/7323888/16b7b74c36f7/nihms-1568549-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d32/7323888/7455a962e04e/nihms-1568549-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d32/7323888/30a9ef30bbb1/nihms-1568549-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d32/7323888/16b7b74c36f7/nihms-1568549-f0003.jpg

相似文献

1
Epidemiology of Follicular Lymphoma.滤泡性淋巴瘤的流行病学。
Hematol Oncol Clin North Am. 2020 Aug;34(4):631-646. doi: 10.1016/j.hoc.2020.02.001. Epub 2020 May 5.
2
Diagnosis and management of follicular lymphoma: A comprehensive review.滤泡性淋巴瘤的诊断与治疗:全面综述。
Eur J Haematol. 2019 Sep;103(3):152-163. doi: 10.1111/ejh.13271. Epub 2019 Jul 4.
3
Risk of transformation by frontline management in follicular and marginal zone lymphomas: a US population-based analysis.滤泡性和边缘区淋巴瘤一线治疗后转化风险:一项基于美国人群的分析。
Blood Adv. 2024 Aug 27;8(16):4423-4432. doi: 10.1182/bloodadvances.2024013499.
4
Follicular lymphoma treatment patterns between 2000 and 2014: a SEER-Medicare analysis of elderly patients.2000 年至 2014 年滤泡性淋巴瘤的治疗模式:老年患者 SEER-Medicare 分析。
Future Oncol. 2020 Mar;16(8):353-365. doi: 10.2217/fon-2019-0660. Epub 2020 Feb 11.
5
Treatment of Histologic Transformation.组织学转化的治疗。
Hematol Oncol Clin North Am. 2020 Aug;34(4):785-794. doi: 10.1016/j.hoc.2020.03.001. Epub 2020 May 5.
6
Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation.通过对地理差异的分析洞察滤泡性淋巴瘤的分子发病机制。
Blood. 2002 Jun 15;99(12):4265-75. doi: 10.1182/blood.v99.12.4265.
7
Racial differences in three major NHL subtypes: descriptive epidemiology.三种主要非霍奇金淋巴瘤亚型的种族差异:描述性流行病学
Cancer Epidemiol. 2015 Feb;39(1):8-13. doi: 10.1016/j.canep.2014.12.001. Epub 2015 Jan 2.
8
Investigation of the incidence trend of follicular lymphoma from 2008 to 2017 in Taiwan and the United States using population-based data.利用基于人群的数据调查 2008 年至 2017 年期间台湾和美国滤泡性淋巴瘤的发病趋势。
PLoS One. 2022 Mar 17;17(3):e0265543. doi: 10.1371/journal.pone.0265543. eCollection 2022.
9
Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020-2025.美国和西欧弥漫性大 B 细胞淋巴瘤(DLBCL)和滤泡性淋巴瘤(FL)的流行病学:2020-2025 年的人口水平预测。
Leuk Lymphoma. 2022 Jan;63(1):54-63. doi: 10.1080/10428194.2021.1975188. Epub 2021 Sep 11.
10
Risk of Second Primary Malignancies in Patients With Follicular Lymphoma: A United States Population-based Study.滤泡性淋巴瘤患者发生第二原发性恶性肿瘤的风险:一项基于美国人群的研究。
Clin Lymphoma Myeloma Leuk. 2017 Sep;17(9):569-574. doi: 10.1016/j.clml.2017.06.028. Epub 2017 Jun 24.

引用本文的文献

1
Efficacy and safety of tazemetostat, an EZH2 inhibitor, in Chinese patients with relapsed/refractory follicular lymphoma: a multicentre, single-arm, phase 2 study.EZH2抑制剂他泽司他在中国复发/难治性滤泡性淋巴瘤患者中的疗效和安全性:一项多中心、单臂、2期研究。
EClinicalMedicine. 2025 Aug 18;87:103399. doi: 10.1016/j.eclinm.2025.103399. eCollection 2025 Sep.
2
Chemokine Receptor Profiles as Predictors of Survival and Early Progression in Follicular Lymphoma.趋化因子受体谱作为滤泡性淋巴瘤生存和早期进展的预测指标
EJHaem. 2025 Aug 28;6(5):e70131. doi: 10.1002/jha2.70131. eCollection 2025 Oct.
3
Incidental vs. symptomatic diagnosis of follicular lymphoma: implications of earlier detection.

本文引用的文献

1
Blood transfusion history and risk of non-Hodgkin lymphoma: an InterLymph pooled analysis.输血史与非霍奇金淋巴瘤风险:InterLymph 汇集分析。
Cancer Causes Control. 2019 Aug;30(8):889-900. doi: 10.1007/s10552-019-01188-w. Epub 2019 Jun 4.
2
Vitamin D status and risk of non-Hodgkin lymphoma: An updated meta-analysis.维生素 D 状态与非霍奇金淋巴瘤风险:一项更新的荟萃分析。
PLoS One. 2019 Apr 29;14(4):e0216284. doi: 10.1371/journal.pone.0216284. eCollection 2019.
3
Non-Hodgkin lymphoma risk and organophosphate and carbamate insecticide use in the north American pooled project.
滤泡性淋巴瘤的偶然诊断与症状性诊断:早期检测的影响
Blood Cancer J. 2025 Jul 3;15(1):116. doi: 10.1038/s41408-025-01322-9.
4
Real-world treatment patterns and clinical outcomes in patients with follicular lymphoma: a SEER-Medicare analysis.滤泡性淋巴瘤患者的真实世界治疗模式与临床结局:一项监测、流行病学和最终结果数据库(SEER)与医疗保险数据分析
Blood Neoplasia. 2025 Feb 21;2(2):100080. doi: 10.1016/j.bneo.2025.100080. eCollection 2025 May.
5
Single-Agent and Associated Therapies with Monoclonal Antibodies: What About Follicular Lymphoma?单克隆抗体的单药治疗及联合疗法:滤泡性淋巴瘤的情况如何?
Cancers (Basel). 2025 May 8;17(10):1602. doi: 10.3390/cancers17101602.
6
Integration of gene mutations in risk prognostication for watch-and-wait follicular lymphoma patients initiating first-line treatment.基因变异在初治观察等待型滤泡性淋巴瘤患者风险预后评估中的整合
Hemasphere. 2025 May 7;9(5):e70141. doi: 10.1002/hem3.70141. eCollection 2025 May.
7
A Cost-Effectiveness Analysis of Mosunetuzumab vs Tisagenlecleucel for Treatment of Third- or Higher-Line (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in Italy.在意大利,莫苏奈妥珠单抗与替沙格赛定用于治疗三线或更高线(3L+)复发或难治性(R/R)滤泡性淋巴瘤(FL)的成本效益分析。
Clinicoecon Outcomes Res. 2025 Apr 16;17:335-348. doi: 10.2147/CEOR.S509907. eCollection 2025.
8
Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi.中期PET在滤泡性淋巴瘤中的预后作用:意大利淋巴瘤基金会对FOLL12试验的事后分析
Blood Adv. 2025 Jun 24;9(12):2927-2934. doi: 10.1182/bloodadvances.2024014790.
9
Molecular Mechanisms in the Transformation from Indolent to Aggressive B Cell Malignancies.惰性B细胞恶性肿瘤向侵袭性B细胞恶性肿瘤转变的分子机制
Cancers (Basel). 2025 Mar 6;17(5):907. doi: 10.3390/cancers17050907.
10
Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma.利妥昔单抗与莫苏单抗治疗三线及以上复发或难治性滤泡性淋巴瘤的疗效和安全性的匹配调整间接比较。
Exp Hematol Oncol. 2025 Mar 5;14(1):30. doi: 10.1186/s40164-025-00610-1.
北美 pooled 项目中的非霍奇金淋巴瘤风险与有机磷和氨基甲酸酯类杀虫剂的使用。
Environ Int. 2019 Jun;127:199-205. doi: 10.1016/j.envint.2019.03.018. Epub 2019 Mar 28.
4
Pesticide use and risk of non-Hodgkin lymphoid malignancies in agricultural cohorts from France, Norway and the USA: a pooled analysis from the AGRICOH consortium.农药使用与法、挪、美三国农业队列中非霍奇金淋巴瘤发病风险:AGRICOH 联盟的汇总分析
Int J Epidemiol. 2019 Oct 1;48(5):1519-1535. doi: 10.1093/ije/dyz017.
5
Anthropometric characteristics, physical activity and risk of hematological malignancies: A systematic review and meta-analysis of cohort studies.人体测量特征、身体活动与血液系统恶性肿瘤风险:队列研究的系统评价和荟萃分析。
Int J Cancer. 2019 Jul 15;145(2):347-359. doi: 10.1002/ijc.32109. Epub 2019 Feb 12.
6
Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts.利妥昔单抗时代滤泡性淋巴瘤发病 10 年内的死因:法国和美国队列的汇总分析。
J Clin Oncol. 2019 Jan 10;37(2):144-152. doi: 10.1200/JCO.18.00400. Epub 2018 Nov 27.
7
Alcohol consumption and risk of hematological malignancies: A meta-analysis of prospective studies.饮酒与血液系统恶性肿瘤风险:前瞻性研究的荟萃分析。
Int J Cancer. 2018 Aug 1;143(3):486-495. doi: 10.1002/ijc.31330. Epub 2018 Mar 30.
8
Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network.专家组对淋巴瘤诊断的影响:法国淋巴病理网络的患者研究。
J Clin Oncol. 2017 Jun 20;35(18):2008-2017. doi: 10.1200/JCO.2016.71.2083. Epub 2017 May 1.
9
Remission of Follicular Lymphoma after Treatment for Hepatitis C Virus Infection.丙型肝炎病毒感染治疗后滤泡性淋巴瘤的缓解
N Engl J Med. 2016 Oct 27;375(17):1699-1701. doi: 10.1056/NEJMc1513288.
10
2016 US lymphoid malignancy statistics by World Health Organization subtypes.2016年按世界卫生组织亚型分类的美国淋巴系统恶性肿瘤统计数据。
CA Cancer J Clin. 2016 Nov 12;66(6):443-459. doi: 10.3322/caac.21357. Epub 2016 Sep 12.